Search results for " Humans"

showing 10 items of 2466 documents

Expression of Cytokeratin 7 and 20 in Pathological Conditions of the Bile Tract

2003

Expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20) helps to establish the origin of biliary and metastatic carcinomas. We investigated the expression of CK7 and CK20 in inflammatory, metaplastic and neoplastic conditions of the bile ducts, and evaluated possible relationships between the CK expression pattern and extrahepatic bile duct/gallbladder carcinomas (EBDCs) or intrahepatic bile duct carcinomas (IBDCs). We used immunohistochemistry for the investigation of 48 formalin-fixed, paraffin-embedded specimens grouped as: A) lithiasic or inflamed surgically resected extrahepatic bile ducts/gallbladders: all were CK7+/CK20+; B) percutaneous liver biopsies from patients with chronic …

medicine.medical_specialtyPathologyIntestinal metaplasia2734Intrahepatic bile ductsBile duct tumors; Cytokeratin 20 (CK20); Cytokeratin 7 (CK7); Intestinal metaplasia; Bile Duct Diseases; Bile Duct Neoplasms; Bile Ducts Extrahepatic; Bile Ducts Intrahepatic; Carcinoma; Cell Transformation Neoplastic; Gallbladder Diseases; Gallbladder Neoplasms; Gene Expression Profiling; Humans; Immunohistochemistry; Intermediate Filament Proteins; Keratin-20; Keratin-7; Keratins; 2734Bile Duct DiseasesGallbladder DiseasesKeratin-20Settore MED/08 - Anatomia PatologicaGastroenterologyIntermediate Filament ProteinPathology and Forensic MedicinePrimary sclerosing cholangitisCytokeratinPrimary biliary cirrhosisIntermediate Filament ProteinsBile Ducts ExtrahepaticInternal medicineBile duct tumormedicineHumansCytokeratin 7 (CK7)Bile Duct NeoplasmGallbladder NeoplasmBile ductbusiness.industryGene Expression ProfilingGallbladderKeratin 20CarcinomaGallbladder DiseaseKeratin-7Bile Duct DiseaseCell Biologymedicine.diseaseImmunohistochemistryBile Ducts IntrahepaticCell Transformation Neoplasticmedicine.anatomical_structureBile Duct NeoplasmsKeratinKeratin 7KeratinsGallbladder NeoplasmsbusinessCytokeratin 20 (CK20)HumanPathology - Research and Practice
researchProduct

Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosi…

2014

GA2LEN EAACI This methods report describes the process of guideline development in detail. It is the result of a systematic literature review using the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) methodology and a structured consensus conference held on 28 and 29 November 2012, in Berlin. It is a joint initiative of the Dermatology Section of the European Academy of Allergy and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) with the participation of delegates of 21 national and international societies. Th…

medicine.medical_specialtyPathologyUrticariahivesdiagnosisImmunologyAlternative medicine610 Medicine & healthmedicineImmunology and AllergyNetwork of excellencemedia_common.cataloged_instanceHumansGuideline developmentEuropean unionGrading (education)whealmedia_common2403 ImmunologyEvidence-Based Medicinebusiness.industryangioedemaConsensus conference10177 Dermatology ClinicGuidelineangioedema; consensus; diagnosis; hives; wheal; Evidence-Based Medicine; Humans; UrticariaSystematic reviewconsensusFamily medicine2723 Immunology and Allergybusiness
researchProduct

Dropout from exercise randomized controlled trials among people with depression: A meta-analysis and meta regression

2015

Abstract Objective Exercise has established efficacy in improving depressive symptoms. Dropouts from randomized controlled trials (RCT’s) pose a threat to the validity of this evidence base, with dropout rates varying across studies. We conducted a systematic review and meta-analysis to investigate the prevalence and predictors of dropout rates among adults with depression participating in exercise RCT’s. Method Three authors identified RCT’s from a recent Cochrane review and conducted updated searches of major electronic databases from 01/2013 to 08/2015. We included RCT’s of exercise interventions in people with depression (including major depressive disorder (MDD) and depressive symptoms…

medicine.medical_specialtyPatient DropoutseducationDepression Exercise Physical activity DropoutPsychological interventionlaw.inventionRandomized controlled triallawPrevalencemedicineHumansMeta-regressionExerciseDepression (differential diagnoses)Dropout (neural networks)Randomized Controlled Trials as TopicDepressive Disorder MajorDepressive DisorderDepressionPhysical activityDropoutMajormedicine.diseaseExercise TherapyPsychiatry and Mental healthClinical PsychologyMeta-analysisPhysical therapyMajor depressive disorderDepression; Dropout; Exercise; Physical activity; Depression; Depressive Disorder Major; Humans; Patient Dropouts; Prevalence; Randomized Controlled Trials as Topic; Exercise Therapy; Psychiatry and Mental Health; Clinical PsychologyExercise prescriptionPsychology
researchProduct

The paradox of the evidence about invasive fungal infections prevention

2016

Invasive fungal infections (IFIs) are characterized by high morbidity and mortality in non-neutropenic critically ill patients. Attributable mortality due to Candida spp. infections ranges from about 42 to 63 % [1, 2]. Data from large observational and retrospective studies show an association between early antifungal treatment and improved survival [3, 4]. Updated clinical practice guidelines for the management of candidiasis have been recently published [5]. In 2006, Playford et al. published a Cochrane systematic review investigating the use of antifungal agents for prevention of IFIs in non-neutropenic critically ill patients [6]. In that review, the outcome of proven IFI was defined as…

medicine.medical_specialtyPediatricsAntifungal AgentsUrinary systemMEDLINECritical Care and Intensive Care Medicinelaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineAntifungal AgentHumansInfection controlInvasive Fungal Infection030212 general & internal medicinebusiness.industryAntifungal Agents; Humans; Invasive Fungal Infections; Critical Care and Intensive Care Medicine030208 emergency & critical care medicineRetrospective cohort studyFungal EsophagitisEditorialmedicine.anatomical_structureObservational studybusinessInvasive Fungal InfectionsHumanRespiratory tractCritical Care
researchProduct

The changing scenario of hepatocellular carcinoma in Italy: an update

2021

Background and aims: Epidemiology of hepatocellular carcinoma (HCC) is changing in most areas of the world. This study aimed at updating the changing scenario of aetiology, clinical presentation, management and prognosis of HCC in Italy during the last 15 years. Methods: Retrospective analysis of the Italian Liver Cancer (ITA.LI.CA) database included 6034 HCC patients managed in 23 centres from 2004 to 2018. Patients were divided into three groups according to the date of cancer diagnosis (2004-2008, 2009-2013 and 2014-2018). Results: The main results were: (i) a progressive patient ageing; (ii) a progressive increase of non-viral cases and, particularly, of ‘metabolic’ and ‘metabolic + alc…

medicine.medical_specialtyPediatricsCarcinoma HepatocellularRadiofrequency ablationmedicine.medical_treatmentSettore MED/12 - GASTROENTEROLOGIAsurvivalepidemiology; hepatocellular carcinoma; survival; treatment; Humans; Italy; Neoplasm Staging; Retrospective Studies; Carcinoma Hepatocellular; Liver Neoplasmslaw.invention03 medical and health sciences0302 clinical medicinelawRetrospective StudieEpidemiologyMedicineHumansNeoplasm StagingRetrospective StudiesHepatologytreatmentbusiness.industryLiver NeoplasmsCarcinomaSettore MED/09 - MEDICINA INTERNACancerHepatocellularhepatocellular carcinomamedicine.diseaseCalendar periodItaly030220 oncology & carcinogenesisHepatocellular carcinomaEtiologyepidemiology; hepatocellular carcinoma; survival; treatment030211 gastroenterology & hepatologyepidemiologyPercutaneous ethanol injectionbusinessLiver cancer
researchProduct

How to manage aspergillosis in non-neutropenic intensive care unit patients.

2014

Invasive aspergillosis has been mainly reported among immunocompromised patients during prolonged periods of neutropenia. Recently, however, non-neutropenic patients in the ICU population have shown an increasing risk profile for aspergillosis. Associations with chronic obstructive pulmonary disease and corticosteroid therapy have been frequently documented in this cohort. Difficulties in achieving a timely diagnosis of aspergillosis in non-neutropenic patients is related to the non-specificity of symptoms and to lower yields with microbiological tests compared to neutropenic patients. Since high mortality rates are typical of invasive aspergillosis in critically ill patients, a high level …

medicine.medical_specialtyPediatricsChronic ObstructiveAntifungal AgentsCritical IllnessPopulationPulmonary diseaseSettore MED/41 - AnestesiologiaReviewNeutropeniaOpportunistic InfectionsAspergillosisCritical Care and Intensive Care MedicineCommunicable DiseasesCommunicable Diseases Emerginglaw.inventionPulmonary DiseaseImmunocompromised HostPulmonary Disease Chronic ObstructiveAspergillosis non-neutropenic ICUlawAdrenal Cortex HormonesRisk FactorsEpidemiologymedicinenon-neutropenicPrevalenceAspergillosisHumansIntensive care medicineeducationEmergingeducation.field_of_studybusiness.industryIncidence (epidemiology)Medicine (all)IncidenceAdrenal Cortex Hormones; Antifungal Agents; Aspergillosis; Communicable Diseases Emerging; Critical Illness; Humans; Incidence; Intensive Care Units; Opportunistic Infections; Prevalence; Prognosis; Pulmonary Disease Chronic Obstructive; Risk Factors; Immunocompromised Host; Critical Care and Intensive Care Medicinemedicine.diseasePrognosisIntensive care unitAdrenal Cortex Hormones; Antifungal Agents; Aspergillosis; Communicable Diseases Emerging; Critical Illness; Humans; Incidence; Intensive Care Units; Opportunistic Infections; Prevalence; Prognosis; Pulmonary Disease Chronic Obstructive; Risk Factors; Immunocompromised HostIntensive Care UnitsCohortICUAdrenal Cortex Hormones; Antifungal Agents; Aspergillosis; Communicable Diseases Emerging; Critical Illness; Humans; Incidence; Intensive Care Units; Opportunistic Infections; Prevalence; Prognosis; Pulmonary Disease Chronic Obstructive; Risk Factors; Immunocompromised Host; Critical Care and Intensive Care Medicine; Medicine (all)businesssepsis aspergillosis icu managementCritical care (London, England)
researchProduct

Tyrosinaemia type Ia without excess of urinary succinylacetone.

1993

medicine.medical_specialtyPediatricsHeptanoates; Amino Acid Metabolism Inborn Errors; Humans; Tyrosine; Female; Child Preschoolbusiness.industryUrinary systemAmino Acid Metabolism Inborn Errormedicine.diseaseHuman geneticsHeptanoatesTyrosinemiaEndocrinologySuccinylacetoneInternal medicineChild PreschoolGeneticsMedicineHumansTyrosineFemaleHeptanoatebusinessAmino Acid Metabolism Inborn ErrorsGenetics (clinical)HumanJournal of inherited metabolic disease
researchProduct

Recommendations for assessing Patient-Reported Outcomes and Health-Related quality of life in clinical trials on allergy: a GA2LEN taskforce position…

2010

The aim of this Global Allergy and Asthma European Network (GA(2)LEN) consensus report is to provide recommendations for patient-reported outcomes (PROs) evaluation in clinical trials for allergic diseases, which constitute a global health problem in terms of physical, psychological economic and social impact. During the last 40 years, PROs have gained large consideration and use in the scientific community, to gain a better understanding of patients' subjective assessment with respect to elements concerning their health condition. They include all health-related reports coming from the patient, without involvement or interpretation by physician or others. PROs assessment should be performe…

medicine.medical_specialtyPediatricsImmunologyPopulationMEDLINEAlergiaHypersensitivity; Humans; Treatment Outcome; Clinical Trials as Topic; Quality of Life; Outcome Assessment (Health Care); Data CollectionOutcome Assessment (Health Care)Quality of life (healthcare)Outcome Assessment Health CareGlobal healthmedicineHypersensitivityHumansImmunology and AllergyeducationAsmaeducation.field_of_studyClinical Trials as Topicbusiness.industryData CollectionGa2LenGuidelinehumanitiesClinical trialTreatment OutcomeFamily medicineInclusion and exclusion criteriaQuality of LifePosition paperbusinessQualidade de VidaHuman
researchProduct

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

2011

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

medicine.medical_specialtyPediatricspml; iris; multiple sclerosis; natalizumabMultiple SclerosisNeurologypmlMEDLINEProgressive MultifocalDermatologyRelapsing-RemittingAntibodies Monoclonal HumanizedAntibodiesLeukoencephalopathyMultiple Sclerosis Relapsing-RemittingNatalizumabLeukoencephalopathyMonoclonalmedicineHumansAdverse effectAntibodies; Monoclonal; Humanized Antibodies; therapeutic use Humans Leukoencephalopathy; Progressive Multifocal; chemically induced Multiple Sclerosis; Relapsing-Remitting; drug therapyHumanizedMultiple sclerosis Natalizumab PML IRISirisbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisLeukoencephalopathy Progressive MultifocalAntibodies MonoclonalGeneral Medicinemedicine.diseasedrug therapyPsychiatry and Mental healththerapeutic usechemically inducednatalizumab multiple sclerosis treatment guidelinesPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusinessmedicine.drug
researchProduct

Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma

2004

Background In asthma T cells are characterized by an increased activation state and by reduced apoptosis. Objective Because the clinical efficacy of inhaled corticosteroids combined with long-acting β 2 -agonists has been widely demonstrated in asthma, we studied, in vitro , the effect of fluticasone propionate (FP) and salmeterol alone and in combination on the activation and apoptosis of peripheral blood T cells (PBTs), on the expression of phosphorylated nuclear factor κB inhibitor (IκBα), and on the nuclear translocation of glucocorticoid receptor (GR) in PBTs from asthmatic subjects. Methods Apoptosis was evaluated on the basis of annexin V binding, whereas the expression of caspases 8…

medicine.medical_specialtyProgrammed cell deathAdolescentT cellT-LymphocytesImmunologyActive Transport Cell NucleusApoptosisAndrostadienes; Active Transport Cell Nucleus; NF-kappa B; Apoptosis; Humans; Albuterol; Receptors Glucocorticoid; Asthma; Child; Caspases; Lymphocyte Activation; Phosphorylation; I-kappa B Proteins; Adolescent; Drug Synergism; T-LymphocytesLymphocyte ActivationGlucocorticoid receptorReceptors GlucocorticoidNF-KappaB Inhibitor alphaAnnexinInternal medicinemedicineHumansImmunology and AllergyAlbuterolPhosphorylationChildSalmeterol XinafoateAndrostadieneChemistryActive Transport Cell NucleuNF-kappa BApoptosiDrug SynergismCaspaseAsthmaAndrostadienesIκBαEndocrinologymedicine.anatomical_structureApoptosisCaspasesFluticasoneI-kappa B ProteinI-kappa B ProteinsSalmeterolGlucocorticoidmedicine.drugHuman
researchProduct